Matt Kapusta, uniQure CEO
July 9, 2024 11:02 AM EDT
R&D
Cell/Gene Tx

UniQure trum­pets mid-stage da­ta for Hunt­ing­ton's dis­ease gene ther­a­py

Max Gelman

Senior Editor

UniQure on Tues­day re­leased new two-year da­ta on its Hunt­ing­ton’s dis­ease gene ther­a­py called AMT-130, send­ing its stock $QURE up by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump an­nounces picks for FDA, CDC; No­var­tis seeks bolt-on deals, rais­es guid­ance; RFK Jr., Elon Musk may find ...

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times